Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
anti-CD45 monoclonal antibody
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
2.
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) Given With CD45 Monoclonal Antibody (MAb) in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Carcinoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
20996
, DELLA, NCT00515957
3.
Phase I Study of a Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
BCM-H-21123
, H 21123, BCM-MASCI, NCT00609258
4.
Phase I Study of Anti-CD45 Monoclonal Antibody and Autologous or Syngeneic LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes in Patients With Relapsed Epstein-Barr Virus (EBV)-Positive Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or EBV-Associated T-/Natural Killer-Lymphoproliferative Disorders
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H19275
, H 19275, BCM-ALDI, NCT00608478
5.
Phase I Study of Anti-CD45 Monoclonal Antibody, Cytarabine, Cyclophosphamide, and Total-Body Irradiation With or Without Alemtuzumab in Patients Undergoing Allogeneic Stem Cell Transplantation For Advanced Leukemia or Other Hematologic Malignancy
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
45 and under
Sponsor:
Other
Protocol IDs:
BCM-H-12870
, H 12870, BCM-ADVL, NCT00601380
6.
Phase I Study of Anti-CD45 Monoclonal Antibody, 14g2a.zeta Chimeric Receptor Transduced Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes, and 14g2a.zeta Transduced Autologous Peripheral Blood T cells in Patients With Advanced Neuroblastoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 64
Sponsor:
Other
Protocol IDs:
BCM-H-13149
, H 13149, BCM-NESTLES, NCT00609206
7.
A Phase I Trial Evaluating the Administration of Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) to Patients With Recurrent or Metastatic EBV-Positive Nasopharygneal Cancer (NPC)
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NPC-CTL
, OCRN #03-NOV-0422, NCT00706316
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute